Search

Saved articles

You have not yet added any article to your bookmarks!

Newsletter image

Subscribe to the Newsletter

Join 10k+ people to get notified about new posts, news and tips.

Do not worry we don't spam!

Pfizer Wins Bidding War for Metsera in $10 Billion Deal

Pfizer Wins Bidding War for Metsera in $10 Billion Deal

Post by : Badri Ariffin

Pfizer has officially sealed a $10 billion deal to acquire obesity drug developer Metsera, putting an end to a high-stakes bidding war with rival Novo Nordisk that gripped the pharmaceutical industry this past week.

The New York-based pharma giant will pay $86.25 per share in cash, which includes $65.60 upfront and a contingent value right of up to $20.65 per share, depending on future milestones. The offer represents a 3.69% premium over Metsera’s closing price on Friday.

This acquisition marks a major strategic move for Pfizer, which has long sought a foothold in the fast-growing weight-loss drug market — an area dominated by Novo Nordisk and Eli Lilly. Pfizer’s earlier in-house efforts to develop effective obesity treatments had fallen short, making Metsera’s promising drug pipeline an attractive target.

Metsera’s leading experimental drugs — MET-097i, a GLP-1 injectable, and MET-233i, an amylin-mimicking compound — are expected to deliver combined peak sales of around $5 billion, according to analysts. Both drugs target metabolic pathways similar to those powering the success of Wegovy and Mounjaro, the blockbuster drugs from Novo and Lilly.

Novo Nordisk, which had made a last-minute counteroffer to regain ground in the obesity segment it once led, has now been edged out. Metsera’s board stated that Novo’s bid carried “unacceptably high legal and regulatory risks,” favoring Pfizer’s more straightforward cash offer.

The acquisition escalated dramatically from Pfizer’s initial $7.3 billion offer in September, reflecting how competition for promising obesity treatments has intensified. With the deal finalized, Pfizer is betting big on Metsera’s science to help it re-enter one of pharma’s most lucrative markets — one expected to exceed $100 billion globally by the end of the decade.

While Metsera remains unprofitable as its drugs are still in development, Pfizer’s financial muscle and global reach could fast-track their path to approval and commercialization. The agreement now heads to Metsera’s shareholders for approval, setting the stage for one of the most significant biotech acquisitions of the year.

Nov. 8, 2025 10:44 a.m. 942

#Global News #Business News

Klang Flash Floods Disrupt Traffic Across Selangor, Malaysia
Nov. 18, 2026 11:37 a.m.
Heavy rain causes Klang flash floods, disrupting traffic in Bukit Raja and Shah Alam as motorists face delays across Selangor, Malaysia
Read More
Xi Jinping Urges Asia-Pacific Nations to Remove Trade Barriers
Nov. 18, 2026 10:20 a.m.
Xi Jinping urges Asia-Pacific economies to remove trade barriers, boost investment and strengthen regional stability at the APEC Summit in China
Read More
Singapore Reviews New US Chip Export Controls Targeting China
Nov. 17, 2026 11:34 a.m.
Singapore reviews US chip export restrictions targeting China's AI access, raising concerns for semiconductor trade and data centre businesses
Read More
APEC Members Emphasise Safe and Responsible Use of Artificial Intelligence
Nov. 17, 2026 10:24 a.m.
APEC members discuss responsible AI use, digital innovation and data governance as China and the US compete for global AI leadership
Read More
Union of European Clubs Challenge UEFA and EFC Over EU Competition Rules
Nov. 16, 2026 5:18 p.m.
UEC files an EU competition complaint against UEFA and EFC, challenging club representation, governance rights and decision-making powers
Read More
US Dollar Extends Rally as Yen Faces Pressure After Weak GDP
Nov. 16, 2026 4:29 p.m.
The US dollar reaches a 19-month high as traders assess Fed rate signals, weak Japan GDP data and possible yen intervention
Read More
Sheikh Hasina Plans December Return to Bangladesh Despite Death Threat
Nov. 16, 2026 3:35 p.m.
Sheikh Hasina plans to return to Bangladesh in December despite death threats, a death sentence and growing political tensions with Dhaka
Read More
Trump Plans to Name Nvidia and AI Firms US National Champions
Nov. 16, 2026 10:01 a.m.
Trump administration plans to name Nvidia, Amazon, Microsoft and OpenAI among US AI national champions to expand overseas and compete with China
Read More
Mohammed Shami Retires From Test Cricket, Eyes White-Ball Career
Nov. 7, 2026 11:10 a.m.
Mohammed Shami retires from Test cricket after 13 years, with 229 wickets. He will continue playing white-ball cricket and domestic matches
Read More
Trending News